BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014;44:22-30. [PMID: 23701387 DOI: 10.1111/hepr.12166] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Wen Y, Feng D, Wu H, Liu W, Li H, Wang F, Xia Q, Gao WQ, Kong X. Defective Initiation of Liver Regeneration in Osteopontin-Deficient Mice after Partial Hepatectomy due to Insufficient Activation of IL-6/Stat3 Pathway. Int J Biol Sci 2015;11:1236-47. [PMID: 26327817 DOI: 10.7150/ijbs.12118] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
2 Pereira TA, Vaz de Melo Trindade G, Trindade Santos E, Pereira FEL, Souza MM. Praziquantel pharmacotherapy reduces systemic osteopontin levels and liver collagen content in murine schistosomiasis mansoni. Int J Parasitol 2021;51:437-40. [PMID: 33493521 DOI: 10.1016/j.ijpara.2020.11.002] [Reference Citation Analysis]
3 Zhou N, Wang K, Fang S, Zhao X, Huang T, Chen H, Yan F, Tang Y, Zhou H, Zhu J. Discovery of a Potential Plasma Protein Biomarker Panel for Acute-on-Chronic Liver Failure Induced by Hepatitis B Virus. Front Physiol 2017;8:1009. [PMID: 29270132 DOI: 10.3389/fphys.2017.01009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Zhu Y, Gao XM, Yang J, Xu D, Zhang Y, Lu M, Zhang Z, Sheng YY, Li JH, Yu XX, Zheng Y, Dong QZ, Qin LX. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma. Cancer Sci 2018;109:710-23. [PMID: 29285854 DOI: 10.1111/cas.13487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
5 Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Mastroiaco V, Vetuschi A, Sferra R, Barnabei R, Capece D, Zazzeroni F, Alesse E. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer 2016;16:3. [PMID: 26728044 DOI: 10.1186/s12885-015-2007-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
6 Yovchev MI, Locker J, Oertel M. Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes. J Hepatol 2016;64:1348-57. [PMID: 26855174 DOI: 10.1016/j.jhep.2016.01.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
7 Arendt BM, Teterina A, Pettinelli P, Comelli EM, Ma DWL, Fung SK, McGilvray ID, Fischer SE, Allard JP. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease. Nutrition. 2019;62:100-107. [PMID: 30870804 DOI: 10.1016/j.nut.2018.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lv H, Lv G, Han Q, Yang W, Wang H. Noncoding RNAs in liver cancer stem cells: The big impact of little things. Cancer Letters 2018;418:51-63. [DOI: 10.1016/j.canlet.2018.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
9 Zhang X, Wu Z, Peng Y, Li D, Jiang Y, Pan F, Li Y, Lai Y, Cui Z, Zhang K. Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Biomed Res Int 2021;2021:6651397. [PMID: 33954191 DOI: 10.1155/2021/6651397] [Reference Citation Analysis]
10 Fouad SA, Mohamed NA, Fawzy MW, Moustafa DA. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma. Hepat Mon 2015;15:e30753. [PMID: 26500684 DOI: 10.5812/hepatmon.30753] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
11 Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J Gastroenterol 2014; 20(47): 17756-17772 [PMID: 25548474 DOI: 10.3748/wjg.v20.i47.17756] [Cited by in CrossRef: 184] [Cited by in F6Publishing: 166] [Article Influence: 23.0] [Reference Citation Analysis]
12 Abdel-Hafiz SM, Hamdy HE, Khorshed FM, Aboushousha TS, Safwat G, Saber MA, Seleem M, Soliman AH. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis. Asian Pac J Cancer Prev 2018;19:1021-7. [PMID: 29693976 DOI: 10.22034/APJCP.2018.19.4.1021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Kaleta B. Osteopontin and Transplantation: Where Are We Now? Arch Immunol Ther Exp (Warsz) 2021;69:15. [PMID: 34019147 DOI: 10.1007/s00005-021-00617-6] [Reference Citation Analysis]
14 Pereira TA, Syn WK, Amâncio FF, Cunha PH, Caporali JF, Trindade GV, Santos ET, Souza MM, Andrade ZA, Witek RP, Secor WE, Pereira FE, Lambertucci JR, Diehl AM. Osteopontin Is Upregulated in Human and Murine Acute Schistosomiasis Mansoni. PLoS Negl Trop Dis 2016;10:e0005057. [PMID: 27755536 DOI: 10.1371/journal.pntd.0005057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
15 Choi SS, Claridge LC, Jhaveri R, Swiderska-Syn M, Clark P, Suzuki A, Pereira TA, Mi Z, Kuo PC, Guy CD, Pereira FE, Diehl AM, Patel K, Syn WK. Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. Clin Sci (Lond) 2014;126:845-55. [PMID: 24438228 DOI: 10.1042/CS20130473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
16 Becerril S, Rodríguez A, Catalán V, Ramírez B, Unamuno X, Gómez-Ambrosi J, Frühbeck G. iNOS Gene Ablation Prevents Liver Fibrosis in Leptin-Deficient ob/ob Mice. Genes (Basel) 2019;10:E184. [PMID: 30818874 DOI: 10.3390/genes10030184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) 2016;9:758-65. [PMID: 27339170 DOI: 10.1158/1940-6207.CAPR-15-0434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
18 Feder S, Bruckmann A, McMullen N, Sinal CJ, Buechler C. Chemerin Isoform-Specific Effects on Hepatocyte Migration and Immune Cell Inflammation. Int J Mol Sci 2020;21:E7205. [PMID: 33003572 DOI: 10.3390/ijms21197205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Monson MS, Settlage RE, McMahon KW, Mendoza KM, Rawal S, El-Nezami HS, Coulombe RA, Reed KM. Response of the hepatic transcriptome to aflatoxin B1 in domestic turkey (Meleagris gallopavo). PLoS One 2014;9:e100930. [PMID: 24979717 DOI: 10.1371/journal.pone.0100930] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
20 Williams JA, Manley S, Ding WX. New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J Gastroenterol 2014; 20(36): 12908-12933 [PMID: 25278688 DOI: 10.3748/wjg.v20.i36.12908] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 7.0] [Reference Citation Analysis]
21 Hu X, Tanaka N, Guo R, Lu Y, Nakajima T, Gonzalez FJ, Aoyama T. PPARα protects against trans-fatty-acid-containing diet-induced steatohepatitis. J Nutr Biochem 2017;39:77-85. [PMID: 27816763 DOI: 10.1016/j.jnutbio.2016.09.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
22 Kwon H, Song K, Han C, Chen W, Wang Y, Dash S, Lim K, Wu T. Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease. Hepatology. 2016;63:1155-1169. [PMID: 26473743 DOI: 10.1002/hep.28289] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
23 Iida T, Wagatsuma K, Hirayama D, Nakase H. Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases? Int J Mol Sci 2017;19:E7. [PMID: 29267211 DOI: 10.3390/ijms19010007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
24 Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 2016; 22(48): 10512-10522 [PMID: 28082803 DOI: 10.3748/wjg.v22.i48.10512] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 182] [Article Influence: 33.0] [Reference Citation Analysis]
25 Matsue Y, Tsutsumi M, Hayashi N, Saito T, Tsuchishima M, Toshikuni N. Serum Osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PLoS One. 2015;10:e0118744. [PMID: 25760884 DOI: 10.1371/journal.pone.0118744] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
26 Patouraux S, Rousseau D, Rubio A, Bonnafous S, Lavallard VJ, Lauron J, Saint-Paul MC, Bailly-Maitre B, Tran A, Crenesse D, Gual P. Osteopontin deficiency aggravates hepatic injury induced by ischemia-reperfusion in mice. Cell Death Dis 2014;5:e1208. [PMID: 24810044 DOI: 10.1038/cddis.2014.174] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
27 Liu H, Li P, Li B, Sun P, Zhang J, Wang B, Jia B. RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN. Tumour Biol 2014;35:11949-58. [PMID: 25172097 DOI: 10.1007/s13277-014-2486-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
28 Khajehahmadi Z, Mohagheghi S, Nikeghbalian S, Geramizadeh B, Khodadadi I, Karimi J, Tavilani H. Liver stiffness correlates with serum osteopontin and TAZ expression in human liver cirrhosis. Ann N Y Acad Sci 2020;1465:117-31. [PMID: 31696937 DOI: 10.1111/nyas.14259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Song Z, Chen W, Athavale D, Ge X, Desert R, Das S, Han H, Nieto N. Osteopontin Takes Center Stage in Chronic Liver Disease. Hepatology 2021;73:1594-608. [PMID: 32986864 DOI: 10.1002/hep.31582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
30 Zhang Y, Gao J, Bao Y, Liu Y, Tong Y, Jin S, Zhao Q. Diagnostic accuracy and prognostic significance of osteopontin in liver cirrhosis and hepatocellular carcinoma: a Meta-analysis. Biomarkers 2021;:1-9. [PMID: 34787036 DOI: 10.1080/1354750X.2021.2008009] [Reference Citation Analysis]
31 Akashi M, Tajiri K, Wada A, Tsuneyama K, Kawai K, Yasumura S, Minemura M, Takahara T, Sugiyama T. A Patient with Non-alcoholic Steatohepatitis Complicated by Multiple Myeloma. Intern Med 2018;57:2013-8. [PMID: 29491288 DOI: 10.2169/internalmedicine.0092-17] [Reference Citation Analysis]
32 Lytle KA, Wong CP, Jump DB. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice. PLoS One 2017;12:e0173376. [PMID: 28422962 DOI: 10.1371/journal.pone.0173376] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
33 Strazzabosco M, Fabris L, Albano E. Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. Gut. 2014;63:1693-1694. [PMID: 25056656 DOI: 10.1136/gutjnl-2014-307712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
34 Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465. [PMID: 24745023 DOI: 10.1155/2014/741465] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
35 Schulien I, Hockenjos B, Schmitt-Graeff A, Perdekamp MG, Follo M, Thimme R, Hasselblatt P. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. Cell Death Differ 2019;26:1688-99. [PMID: 30778201 DOI: 10.1038/s41418-018-0239-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
36 Bruha R, Jachymova M, Petrtyl J, Dvorak K, Lenicek M, Urbanek P, Svestka T, Vitek L. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol 2016; 22(12): 3441-3450 [PMID: 27022226 DOI: 10.3748/wjg.v22.i12.3441] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
37 Wang G, Chen S, Zhao C, Li X, Zhao W, Yang J, Chang C, Xu C. Comparative analysis of gene expression profiles of OPN signalling pathway in four kinds of liver diseases. J Genet 2016;95:741-50. [DOI: 10.1007/s12041-016-0673-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
38 Fujii H, Kawada N. Fibrogenesis in alcoholic liver disease. World J Gastroenterol 2014; 20(25): 8048-8054 [PMID: 25009376 DOI: 10.3748/wjg.v20.i25.8048] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
39 Patouraux S, Rousseau D, Bonnafous S, Lebeaupin C, Luci C, Canivet CM, Schneck A, Bertola A, Saint-paul M, Iannelli A, Gugenheim J, Anty R, Tran A, Bailly-maitre B, Gual P. CD44 is a key player in non-alcoholic steatohepatitis. Journal of Hepatology 2017;67:328-38. [DOI: 10.1016/j.jhep.2017.03.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
40 Wang Y, Zhou W, Wu C, Zhang Y, Lin T, Sun Y, Liu W, Tao T. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study. Reprod Biol Endocrinol 2018;16:31. [PMID: 29587769 DOI: 10.1186/s12958-018-0331-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
41 Pereira TA, Syn WK, Machado MV, Vidigal PV, Resende V, Voieta I, Xie G, Otoni A, Souza MM, Santos ET. Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. Clin Sci (Lond). 2015;129:875-883. [PMID: 26201095 DOI: 10.1042/cs20150117] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
42 Liu L, Lu J, Ye C, Lin L, Zheng S, Zhang H, Lan Q, Xue Y. Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure. Biomed Rep 2018;8:166-71. [PMID: 29435276 DOI: 10.3892/br.2017.1027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 He W, Dai C. Key Fibrogenic Signaling. Curr Pathobiol Rep 2015;3:183-92. [PMID: 25973345 DOI: 10.1007/s40139-015-0077-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
44 Wang C, He M, Peng J, Li S, Long M, Chen W, Liu D, Yang G, Zhang L. Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine. 2020;125:154837. [PMID: 31514105 DOI: 10.1016/j.cyto.2019.154837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Carranza-Trejo AM, Vetvicka V, Vistejnova L, Kralickova M, Montufar EB. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:783-96. [PMID: 33557653 DOI: 10.1080/17474124.2021.1887730] [Reference Citation Analysis]
46 Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, Basta G, Gastaldelli A, Del Ry S. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine 2017;99:59-65. [PMID: 28711012 DOI: 10.1016/j.cyto.2017.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
47 Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22:10512-10522. [PMID: 28082803 DOI: 10.3748/wjg.v22.i48.10512.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Lee SH, Park JW, Woo SH, Go DM, Kwon HJ, Jang JJ, Kim DY. Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice. Oncotarget 2016;7:87219-31. [PMID: 27888617 DOI: 10.18632/oncotarget.13529] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
49 Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, Rashid A, Gagea M, Zabludoff S, Kalluri R, Beretta L. miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res. 2015;75:1859-1867. [PMID: 25769721 DOI: 10.1158/0008-5472.can-14-1254] [Cited by in Crossref: 59] [Cited by in F6Publishing: 34] [Article Influence: 8.4] [Reference Citation Analysis]
50 Pereira TA, Syn WK, Pereira FE, Lambertucci JR, Secor WE, Diehl AM. Serum osteopontin is a biomarker of severe fibrosis and portal hypertension in human and murine schistosomiasis mansoni. Int J Parasitol 2016;46:829-32. [PMID: 27729270 DOI: 10.1016/j.ijpara.2016.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
51 Qu BG. Inflammatory and immune changes and treatment in patients with fatty liver disease. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2931-2942 [DOI: 10.11569/wcjd.v24.i19.2931] [Reference Citation Analysis]
52 Pohl R, Feder S, Haberl EM, Rein-fischboeck L, Weiss TS, Spirk M, Bruckmann A, Mcmullen N, Sinal CJ, Buechler C. Chemerin Overexpression in the Liver Protects against Inflammation in Experimental Non-Alcoholic Steatohepatitis. Biomedicines 2022;10:132. [DOI: 10.3390/biomedicines10010132] [Reference Citation Analysis]
53 Shirasaki T, Honda M, Yamashita T, Nio K, Shimakami T, Shimizu R, Nakasyo S, Murai K, Shirasaki N, Okada H, Sakai Y, Sato T, Suzuki T, Yoshioka K, Kaneko S. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Sci Rep 2018;8:13143. [PMID: 30177680 DOI: 10.1038/s41598-018-31421-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
54 Gilbert KM, Reisfeld B, Zurlinden TJ, Kreps MN, Erickson SW, Blossom SJ. Modeling toxicodynamic effects of trichloroethylene on liver in mouse model of autoimmune hepatitis. Toxicol Appl Pharmacol 2014;279:284-93. [PMID: 25026505 DOI: 10.1016/j.taap.2014.07.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
55 Gu J, Yao M, Yao D, Wang L, Yang X, Yao D. Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation. J Clin Transl Hepatol. 2016;4:123-130. [PMID: 27350942 DOI: 10.14218/jcth.2016.00010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
56 Leung JC, Loong TC, Pang J, Wei JL, Wong VW. Invasive and non-invasive assessment of portal hypertension. Hepatol Int 2018;12:44-55. [PMID: 28361299 DOI: 10.1007/s12072-017-9795-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
57 Bruha R, Vitek L, Smid V. Osteopontin - A potential biomarker of advanced liver disease. Ann Hepatol 2020;19:344-52. [PMID: 32005637 DOI: 10.1016/j.aohep.2020.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
58 Napoli S, Scuderi C, Gattuso G, Bella VD, Candido S, Basile MS, Libra M, Falzone L. Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. Cells 2020;9:E1151. [PMID: 32392801 DOI: 10.3390/cells9051151] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]